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a b s t r a c t 
A 52-year-old woman presented to the emergency department with several days of pro- 
gressive dyspnoea and thoracic pain. Her medical history included a (recurrent) anaplas- 
tic meningioma, for which she was treated with surgery and radiotherapy. A chest X-ray 
showed occurrence of total opacification of the left lower lobe and a chest computed to- 
mography demonstrated a pleural mass of 12 × 9 × 15 cm in the left lower lobe. Biopsy of 
the pleural mass revealed a metastasis of the patient’s anaplastic meningioma. Extracranial 
metastases from meningioma are extremely uncommon ( ≤ 0.1%-0.2% of cases), but impor- 
tant for a patient’s prognosis. 
© 2020 The Authors. Published by Elsevier Inc. on behalf of University of Washington. 
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Meningioma is with 30% the most frequent occurring malig-
nancy of the central nervous system, and has an incidence
rate of 4.5 cases in 100,000 people each year. Meningiomas
originate from the meninges and are typically associated with
genetic alterations in the neurofibromatosis type 2 gene. Di-
agnosis is based on a magnetic resonance imaging (MRI) scan
and confirmed by histopathological analysis of the tumor [1] .
Meningiomas are graded by the World Health Organisation
(WHO) classification system in 3 subtypes [2] . In approxi-
mately 80% of cases the meningioma is benign (WHO grade 1)
[3] . The surplus consists of atypical meningioma (WHO grade
2; 15% to 20%) and anaplastic -or malignant-meningioma
(WHO grade 3; 1% to 3%) [1 ,4] . ∗ Corresponding author. 
E-mail address: g.veerman@erasmusmc.nl (G.D.M. Veerman). 
https://doi.org/10.1016/j.radcr.2020.10.020 
1930-0433/© 2020 The Authors. Published by Elsevier Inc. on behalf of U
CC BY license ( http://creativecommons.org/licenses/by/4.0/ ) First-line treatment of benign meningioma is largely
dependent on patient specific characteristics (eg, age and
performance status) and patient preference. In higher grade
meningioma however, first-line treatment is preferably sur-
gical resection, and in case of grade 3 meningioma followed
by high-dose radiotherapy, in order to minimize the change
of local disease recurrence [5] . Nevertheless, in 50%-90%
of anaplastic meningiomas the tumor recurs [3 ,6] . Hence
frequent follow-up by MRI is additionally recommended
[5] . When anaplastic meningioma does locally recur or
metastasize to other locations, treatment options are lim-
ited. Therefore, the median overall survival of anaplastic
meningioma is less than 2 years [7] . At reoccurrence, surgical
resection or reirradiation of the tumor(s) could be possible,
but clinical efficacy data are solely from case reports. Current
guidelines do not (yet) consider pharmacotherapy to have aniversity of Washington. This is an open access article under the 
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Fig. 1 – Magnetic resonance image of the brain in April 2019; 

















































place in the treatment of recurrent or metastasized anaplastic
meningioma [3 ,5] . 
This case report describes the discovery of a rare
pleural metastasis in a patient with recurrent anaplastic
meningioma. 
Case report 
A 52-year-old woman presented to the emergency department
with complaints of several days of progressive dyspnea and
thoracic pain. Her medical history included a meningioma
in the right occipital lobe since 2010, which was discovered
after causing a homonymous hemianopia at the patient’sFig. 2 – Magnetic resonance images of the brain in February 2020
disease of the anaplastic meningioma in both occipital lobes. left side. The first diagnosis was of an atypical meningioma.
The tumor’s driver mutation was the neurofibromatosis 2
exon 8 c.784C > T mutation. Initially, the patient was treated
with surgery and adjuvant radiotherapy. In 2013, there was
radiologic recurrence and she was again treated with surgery
and adjuvant radiotherapy. Once more, the pathological
diagnosis was atypical meningioma. The same occurred in
2015, although this time the patient received adjuvant proton
therapy as well. In 2018 the follow-up MRI-scan showed
possible local disease recurrence or radiation necrosis, hence
dexamethasone and bevacizumab (a vascular endothelial
growth factor receptor antibody) were started. The beva-
cizumab was stopped in the beginning 2019, because the
patient suffered from polyneuropathy and she had clinically
improved during treatment. However, in the second half of
2019 there was eminent disease recurrence seen on MRI in
the occipital lobe ( Fig. 1 ). No systemic or local treatment
was given at that time. Meanwhile, the patient was given
a ventricular-peritoneal drain, because thrombosis in the
superior sagittal sinus caused an increase in intracra-
nial pressure. Debulking of the tumor was performed and
histopathological analysis showed an anaplastic menin-
gioma with the known mutation in the neurofibromato-
sis gene. One month prior to presentation, a follow-up
MRI-scan of the brain ( Fig. 2 ) showed local growth of
the meningioma. Since the patient suffered from vi-
sual impairment, she used 4 mg dexamethasone twice
daily. 
In the emergency department, the patient’s vital signs
revealed a mild hypoxia, for which 3 L/min supplemental
oxygen was given to obtain an oxygen saturation of 95%.
Her respiratory rate was 18/min and she had normal hemo-
dynamic parameters. Blood results presented low infection
parameters and an elevated d-dimer of 4.4 mg/L (normal < 0.5
mg/L). A chest X-ray was made, which showed occurrence
of opacification of the left lower lobe ( Fig. 3 ), compared to a
chest X ray 3 months prior to presentation. This finding was
suggestive for unilateral pleural effusion, a lobular pneumo-
nia, atelectasis, or an intrathoracic mass. Hence a computed
tomography pulmonary angiography ( Fig. 4 ) was made, that
showed central and right-sided (sub-)segmental pulmonary; axial, coronal, and sagittal image showing progression of 
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Fig. 3 – Chest X-ray at presentation; total opacification of 
the left lower lobe. 
Fig. 4 – Chest computed tomography pulmonary 
angiography at presentation; central and right-sided 
subsegmental pulmonary embolisms (arrow 1), and a 














Fig. 5 – Chest computed tomography one month after 
presentation; growing pleural mass in the left lower lobe 






























embolisms (arrow 1), and a pleural mass of 12 × 9 × 15 cm in
the left lower lobe (arrow 2). 
The patient was admitted for 9 days in total, during which
she was treated with low-molecular weight heparin for the
pulmonary lung embolisms. Throughout the admission, the
dyspnea and thoracic pain gradually improved. Meanwhile, a
biopsy of the pleural mass was performed. Genome-wide pro-
filing with a methylation assay clustered the tumor as ma-
lignant meningioma, herewith confirming the tumor to be a
pleural metastasis of the anaplastic meningioma. 
In the weeks after discharge, the patient’s condition and
eyesight declined. A follow-up scan showed progression of the
pleural metastasis and a new pericardial mass ( Fig. 5 ). Because
of further clinical deterioration, the patient did not receive
further palliative anticancer treatment and she died approxi-
mately 1 month later. Discussion 
This case report describes the discovery of a rare pleural
metastasis in a patient with recurrent anaplastic menin-
gioma. The patient presented with common respiratory
complains and an elevated d-dimer. The computed tomog-
raphy pulmonary angiography showed multiple pulmonary
embolisms, but also a large pleural mass. This pleural tumor
was pathologically diagnosed as a metastasis of the patient’s
known anaplastic meningioma. Extracranial metastases
from a meningioma are extremely uncommon ( ≤ 0.1%-
0.2% of cases) and involve mostly pulmonary metastases
[8–10] . The size and presentation of the metastasis in this
case are furthermore remarkable. Characteristic for pleural
metastases is the rounded angle between the tumour and the
lung parenchyma. 
The patient’s disease history is typical for anaplastic
meningioma; after multiple local recurrences of a lower
grade (in this case atypical) meningioma, it differentiates to
a pathological anaplastic meningioma and gains the potency
to metastasize [11] . At the time discovery in the emergency
department, the primary tumor could still be from a different
origin. In this case, the conclusive diagnosis could be based
on specific genetic testing of the tumor and was positive for
meningioma. The pathologic confirmation is essential for
determination of possible treatment options; if this tumor
was the metastasis of another primary tumor, more specific-
and registered-therapy may have been given. This hence
attributes valuable information to a patient’s prognosis,
because metastatic disease of anaplastic meningioma is an
infaust diagnosis [11] . 
Patient consent statement 
The late husband of the patient was informed and gave in-
formed consent for the usage of all necessary images and
medical information for this case report. 
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